AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12102380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10459328 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 50
Study 10459328 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study 8546294 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (1.25 mg) with morphine (1 mg.ml‐1)
Number of subjects: 145
Study 8546294 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg) with morphine (1 mg.ml‐1)
Number of subjects: 145
Study 8546294 — intervention group
Group type: COMPARATOR
Intervention: Morphine (1 mg.ml‐1) alone
Number of subjects: 145
Study 2201992 — intervention group
Group type: EXPERIMENTAL
Intervention: oral acyclovir
Number of subjects: 21
Study 2201992 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 21
Study 360779 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline-N-oxide
Number of subjects: 43
Study 360779 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 43
Study 31250889 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g BCAA
Number of subjects: 45
Study 31250889 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g BCKA
Number of subjects: 45
Study 31250889 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g MILK
Number of subjects: 45
Study 29879719 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine plus Yufeng Ningxin tablets
Number of subjects: 242
Study 29879719 — intervention group
Group type: COMPARATOR
Intervention: Flunarizine
Number of subjects: 242
Study 27222260 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised formal neonatal resuscitation training (SFNRT)
Number of subjects: 66162
Study 27222260 — intervention group
Group type: EXPERIMENTAL
Intervention: Teamwork training with simulation
Number of subjects: 66162
Study 25195137 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 13
Study 25195137 — intervention group
Group type: COMPARATOR
Intervention: Control (without NIV)
Number of subjects: 13
Study 22429354 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (thoracic epidural block)
Number of subjects: 60
Study 22429354 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil (intravenous)
Number of subjects: 60
Study 22429354 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (intravenous)
Number of subjects: 60
Study 22429354 — intervention group
Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 60
Study 20124231 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG, 0.5 g/kg
Number of subjects: 12
Study 20124231 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 12
Study 18853648 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor rehabilitation after radical mastectomy
Number of subjects: 86
Study 18853648 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with large mass (>69.2 kg), WHR (>0.94), Quetelet's (>448.7), Rohrer's (>1.76), and Pignet-Verwaeck's (107.7)
Number of subjects: 86
Study 18853648 — intervention group
Group type: EXPERIMENTAL
Intervention: Slim body build and low index values
Number of subjects: 86
Study 16221778 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine
Number of subjects: 2781
Study 16221778 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis A vaccine (control)
Number of subjects: 2781
Study 12135030 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 mg budesonide CIR once daily
Number of subjects: 200
Study 12135030 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5 mg budesonide CIR b.i.d.
Number of subjects: 200
Study 12135030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 9989566 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 29
Study 9989566 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 29
Study 8578018 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxithromycin (low dose for a long period of time)
Number of subjects: 0
Study 8578018 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 0
Study 2162296 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose as the sole non-protein energy source
Number of subjects: 10
Study 2162296 — intervention group
Group type: COMPARATOR
Intervention: Glucose-lipid mixture
Number of subjects: 10
Study 7468062 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (5000 units every 12 hours for 10 days)
Number of subjects: 210
Study 7468062 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin + Dihydroergotamine (0.5 mg at the same intervals as heparin)
Number of subjects: 210
Study 7468062 — intervention group
Group type: COMPARATOR
Intervention: Saline (acting as control)
Number of subjects: 210
Study 31779689 — intervention group
Group type: EXPERIMENTAL
Intervention: GP or nurse-led brief advice about e‐cigarettes, an e‐cigarette starter pack, practical support booklet, and telephone support from experienced vapers and online video tutorials.
Number of subjects: 0
Study 31779689 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study 29335051 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month recall (3-MR) and 6-month recall (6-MR)
Number of subjects: 0
Study 29335051 — intervention group
Group type: COMPARATOR
Intervention: 6-month recall (6-MR)
Number of subjects: 0
Study 25927298 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention targeting to narrow SES differences in energy balance-related behaviors (EBRBs) in preschool settings.
Number of subjects: 800
Study 25927298 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometer usage for seven days to measure physical activity (PA).
Number of subjects: 800
Study 25927298 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaires completed by parents and preschool personnel regarding EBRBs, social and physical environments, and SES factors.
Number of subjects: 800
Study 25927298 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological measurements including hair and saliva samples.
Number of subjects: 800
Study 25927298 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of preschool environment observed.
Number of subjects: 800
Study 23337477 — intervention group
Group type: EXPERIMENTAL
Intervention: lanreotide Autogel 60 mg
Number of subjects: 32
Study 23337477 — intervention group
Group type: EXPERIMENTAL
Intervention: lanreotide Autogel 90 mg
Number of subjects: 32
Study 23337477 — intervention group
Group type: EXPERIMENTAL
Intervention: lanreotide Autogel 90 mg (adjusted according to clinical responses)
Number of subjects: 32
Study 21890085 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily
Number of subjects: 199
Study 21890085 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg/day
Number of subjects: 199
Study 19052047 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing training
Number of subjects: 183
Study 19052047 — intervention group
Group type: COMPARATOR
Intervention: Asthma education
Number of subjects: 183
Study 18625052 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention 1
Number of subjects: 389
Study 18625052 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention 2
Number of subjects: 389
Study 18625052 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention 3
Number of subjects: 389
Study 18625052 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention 4
Number of subjects: 389
Study 15762970 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training (n=8)
Number of subjects: 19
Study 15762970 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=11)
Number of subjects: 19
Study 15762970 — intervention group
Group type: COMPARATOR
Intervention: Comparison between groups
Number of subjects: 19
Study 12038945 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-mg nicotine lozenge
Number of subjects: 1818
Study 12038945 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-mg nicotine lozenge
Number of subjects: 1818
Study 12038945 — intervention group
Group type: EXPERIMENTAL
Intervention: Active lozenge
Number of subjects: 1818
Study 12038945 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenge
Number of subjects: 1818
Study 10203653 — intervention group
Group type: EXPERIMENTAL
Intervention: McCall-type culdeplasty
Number of subjects: 100
Study 10203653 — intervention group
Group type: COMPARATOR
Intervention: Vaginal Moschcowitz-type procedure
Number of subjects: 100
Study 10203653 — intervention group
Group type: COMPARATOR
Intervention: Peritoneal closure only
Number of subjects: 100
Study 7702188 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (DIL)
Number of subjects: 90
Study 7702188 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (NTG)
Number of subjects: 90
Study 7702188 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem/Nitroglycerin (DIL/NTG)
Number of subjects: 90
Study 2665802 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ultrasound
Number of subjects: 414
Study 2665802 — intervention group
Group type: EXPERIMENTAL
Intervention: Active pulsed electromagnetic energy
Number of subjects: 414
Study 2665802 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapies
Number of subjects: 414
Study 339214 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily atenolol (100 mg)
Number of subjects: 12
Study 339214 — intervention group
Group type: COMPARATOR
Intervention: Twice daily atenolol (100 mg or 50 mg)
Number of subjects: 12
Study 29806553 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose solution (50 g/300 ml of water)
Number of subjects: 25
Study 29806553 — intervention group
Group type: COMPARATOR
Intervention: Plain water
Number of subjects: 25
Study 31623656 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional rehabilitation combined with active tDCS
Number of subjects: 80
Study 31623656 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation combined with sham tDCS
Number of subjects: 80
Study 28877238 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment manoeuvre (RM) with positive end expiratory pressure (PEEP)
Number of subjects: 60
Study 28877238 — intervention group
Group type: COMPARATOR
Intervention: Positive end expiratory pressure (PEEP) without recruitment manoeuvre (RM)
Number of subjects: 60
Study 25304832 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative physical activity intervention (PAI) for 6 weeks, including weekly individual face-to-face sessions with tailored instruction in behavioral strategies
Number of subjects: 75
Study 25304832 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative physical activity intervention (PAI) for 6 weeks
Number of subjects: 75
Study 25304832 — intervention group
Group type: COMPARATOR
Intervention: Standard presurgical care (SC)
Number of subjects: 75
Study 23593633 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix allograft (ADMA) with coronally positioned flap (CPF)
Number of subjects: 20
Study 23593633 — intervention group
Group type: COMPARATOR
Intervention: Coronally positioned flap (CPF) alone
Number of subjects: 20
Study 21311347 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) with a frequency of 30 Hz and an amplitude of 6.5 mm in 4 bouts of 30 seconds with 30 seconds of rest between bouts, followed by 3 countermovement jumps (CMJs) with different rest intervals (immediate, 30 seconds, 1 minute, 2 minutes, or 4 minutes)
Number of subjects: 30
Study 21311347 — intervention group
Group type: COMPARATOR
Intervention: Control condition: squats with no WBV
Number of subjects: 30
Study 19820017 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg anastrozole daily
Number of subjects: 69
Study 19820017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 16829029 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 mcg of selenomethionine daily)
Number of subjects: 37
Study 16829029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 15277409 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic index (LGI) diet
Number of subjects: 12
Study 15277409 — intervention group
Group type: COMPARATOR
Intervention: High-glycemic index (HGI) diet
Number of subjects: 12
Study 11576045 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 0.4 mg
Number of subjects: 25
Study 11576045 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 10 mg
Number of subjects: 25
Study 11576045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 9150660 — intervention group
Group type: EXPERIMENTAL
Intervention: High lighting levels
Number of subjects: 25
Study 9150660 — intervention group
Group type: COMPARATOR
Intervention: Dim room lighting
Number of subjects: 25
Study 9150660 — intervention group
Group type: COMPARATOR
Intervention: Dark lighting
Number of subjects: 25
Study 7911175 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 134
Study 7911175 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 134
Study 3582483 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen syrup 1 mg b.i.d. for 8 days
Number of subjects: 6
Study 3582483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 3582483 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline syrup 6 mg/kg
Number of subjects: 6
Study 30035416 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney transplant recipients
Number of subjects: 110
Study 30035416 — intervention group
Group type: COMPARATOR
Intervention: Hemodialysis patients (Control)
Number of subjects: 110
Study 28842086 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided nerve block (NB)
Number of subjects: 40
Study 28842086 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 40
Study 26256138 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot reflexology
Number of subjects: 96
Study 26256138 — intervention group
Group type: COMPARATOR
Intervention: Placebo (simple surface touching)
Number of subjects: 96
Study 26256138 — intervention group
Group type: COMPARATOR
Intervention: Control (routine care)
Number of subjects: 96
Study 23743162 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiqi Huaju Formula (CHF)
Number of subjects: 43
Study 23743162 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 43
Study 21445642 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled sevoflurane (group S)
Number of subjects: 60
Study 21445642 — intervention group
Group type: COMPARATOR
Intervention: Intravenous propofol (group P)
Number of subjects: 60
Study 21445642 — intervention group
Group type: COMPARATOR
Intervention: Intravenous midazolam (group M)
Number of subjects: 60
Study 18159096 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and cilostazol (group I, n=141)
Number of subjects: 280
Study 18159096 — intervention group
Group type: COMPARATOR
Intervention: Aspirin and clopidogrel (group II, n=139)
Number of subjects: 280
Study 16957901 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin-resistant Pseudomonas strains
Number of subjects: 0
Study 16957901 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin-susceptible Pseudomonas strains
Number of subjects: 0
Study 16957901 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin resistance
Number of subjects: 0
Study 16957901 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin-resistant and susceptible strains
Number of subjects: 0
Study 14610641 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate (2 mg) injections every 3 months plus daily calcium supplements (500 mg)
Number of subjects: 115
Study 14610641 — intervention group
Group type: COMPARATOR
Intervention: Daily oral alfacalcidol (1 microg) plus daily calcium supplements (500 mg)
Number of subjects: 115
Study 10913058 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive exercise programme
Number of subjects: 64
Study 10913058 — intervention group
Group type: COMPARATOR
Intervention: Conservative exercise programme
Number of subjects: 64
Study 8682682 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified positioning and mobilization routine (head of the bed elevated to 45 degrees, ambulated briefly at bedside 4 hours after angiography)
Number of subjects: 29
Study 8682682 — intervention group
Group type: COMPARATOR
Intervention: Control group (6 hours of bed rest after cardiac angiography)
Number of subjects: 29
Study 1410326 — intervention group
Group type: EXPERIMENTAL
Intervention: Iotrolan
Number of subjects: 158
Study 1410326 — intervention group
Group type: COMPARATOR
Intervention: Iopamidol
Number of subjects: 158
Study 3885173 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination vindesine and cisplatin (DDP)
Number of subjects: 0
Study 3885173 — intervention group
Group type: COMPARATOR
Intervention: Single-agent vindesine (DVA)
Number of subjects: 0
Study 28671753 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy-A (glucose-dependent therapies with a non-sulphonylurea OAM and a glucagon-like peptide-1 receptor agonist)
Number of subjects: 192
Study 28671753 — intervention group
Group type: COMPARATOR
Intervention: Strategy-B (non-glucose-dependent therapies with sulphonylurea and insulin glargine)
Number of subjects: 192
Study 28671753 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy-A
Number of subjects: 192
Study 28671753 — intervention group
Group type: COMPARATOR
Intervention: Strategy-B
Number of subjects: 192
Study 27244793 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing intervention (1 group session and 8 individual sessions)
Number of subjects: 1355
Study 27244793 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 1355
Study 25014995 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based ESRA-C intervention delivered to patients' homes or to a tablet in clinic.
Number of subjects: 517
Study 25014995 — intervention group
Group type: COMPARATOR
Intervention: ESRA-C assessment only (control group).
Number of subjects: 517
Study 25014995 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based ESRA-C intervention.
Number of subjects: 517
Study 25014995 — intervention group
Group type: COMPARATOR
Intervention: Control group (ESRA-C assessment only).
Number of subjects: 517
Study 25014995 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' verbal reports (intervention group).
Number of subjects: 517
Study 22199163 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity resistance training for 18 weeks
Number of subjects: 10
Study 20567172 — intervention group
Group type: EXPERIMENTAL
Intervention: Didactic study arm using the cystoscopy model
Number of subjects: 29
Study 18672827 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia programme
Number of subjects: 30
Study 18672827 — intervention group
Group type: COMPARATOR
Intervention: Leaflet group
Number of subjects: 30
Study 15792209 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive technique with a posterolateral incision no longer than 10 cm
Number of subjects: 120
Study 15792209 — intervention group
Group type: COMPARATOR
Intervention: Standard posterolateral approach
Number of subjects: 120
Study 14563575 — intervention group
Group type: EXPERIMENTAL
Intervention: Polytetrafluoroethylene (PTFE)‐membrane‐covered stent (Jostent Stentgraft)
Number of subjects: 211
Study 14563575 — intervention group
Group type: COMPARATOR
Intervention: Conventional stent (Jostent Flex)
Number of subjects: 211
Study 14563575 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PTFE-membrane-covered stent and conventional stent)
Number of subjects: 211
Study 10793318 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol augmentation (2.5 mg x 3/d) with paroxetine (60 mg/d)
Number of subjects: 14
Study 10793318 — intervention group
Group type: COMPARATOR
Intervention: Placebo augmentation with paroxetine (60 mg/d)
Number of subjects: 14
Study 8899094 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg twice daily for 1 week, then once daily for 3 weeks
Number of subjects: 100
Study 8899094 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg twice daily for 1 week, then once daily for 3 weeks
Number of subjects: 100
Study 1701718 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-based method for the detection of sleep phasic events (vertex waves and K complexes)
Number of subjects: 6
Study 1701718 — intervention group
Group type: COMPARATOR
Intervention: Model-based method for the detection of sleep phasic events
Number of subjects: 6
Study 6194757 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination antibiotic therapy (sulbenicillin and amikacin) with S‐sulfonated gamma‐globulin (Group A)
Number of subjects: 50
Study 6194757 — intervention group
Group type: COMPARATOR
Intervention: Combination antibiotic therapy (sulbenicillin and amikacin) without S‐sulfonated gamma‐globulin (Group B)
Number of subjects: 50
Study 31566309 — intervention group
Group type: EXPERIMENTAL
Intervention: Encorafenib, binimetinib, and cetuximab (triplet-therapy group)
Number of subjects: 665
Study 31566309 — intervention group
Group type: EXPERIMENTAL
Intervention: Encorafenib and cetuximab (doublet-therapy group)
Number of subjects: 665
Study 31566309 — intervention group
Group type: COMPARATOR
Intervention: Control group (cetuximab and irinotecan or cetuximab and FOLFIRI)
Number of subjects: 665
Study 28657216 — intervention group
Group type: EXPERIMENTAL
Intervention: Rikkunshito with standard antiemetics
Number of subjects: 0
Study 28657216 — intervention group
Group type: COMPARATOR
Intervention: Control group (antiemetics only)
Number of subjects: 0
Study 25897047 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound imaging
Number of subjects: 418
Study 25897047 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-infrared vascular imaging
Number of subjects: 418
Study 23411644 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal mobilization techniques of the upper cervical spine
Number of subjects: 36
Study 23411644 — intervention group
Group type: COMPARATOR
Intervention: Massage therapy of the neck region
Number of subjects: 36
Study 23411644 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Neck Disability Index (NDI)
Number of subjects: 36
Study 22134569 — intervention group
Group type: EXPERIMENTAL
Intervention: GA 70% peeling
Number of subjects: 63